(mRNA Startup, co-founded by Drew Weissman) Leading the development of tissue-specific mRNA/LNP therapies for lung fibrosis and cancer. Managing biology and pipeline processes while ensuring the timely delivery of key milestones and deliverables.• Established preclinical workflows to advance programs from discovery to IND filing• Contributed to strategic planning, in-licensing, and financing activities as a core team member• Developed collaborations with CROs and external KOLs to expand research capabilities• Presented findings at internal and external meetings through scientific abstracts and posters

(CBC-incubated mRNA Start-up with $140M Series B)Developed innovative mRNA-based immune modulatory therapeutics for cancer and autoimmune diseases. Led 6 preclinical bispecific antibody portfolios, from concept to developmental candidate stage. • Managed a 15-member cross-functional team across multiple global locations • Led programs for mRNA-encoded Bispecific (PDL1 x VEGF), Immunocytokines (PDL1-41BBL), Imunnotoxins (HER2-DT) and anti-inflammatory cytokines (TNF-α, IL-1β, 6,12)• Delivered a developmental candidate for PDL1 x VEGF, with enhanced 10x anti-tumor efficacy and 2x survival benefits in syngeneic and orthotopic mouse models • Proposed novel targets along with project plans to guide technical teams through lead identification, lead optimization and pre-clinical development• Pre-clinical progress published at SITC 2023, 1 year after project initiation• Supervised junior scientists, managed external CRO relationships, negotiated contracts, and conducted due diligence [ 2023 SITC: mRNA-encoded PDL1 x VEGF bispecific ]

(FL72, Therapeutic Vaccine Company) Led the in vitro pharmacology team for optimization of the therapeutic vaccine platform and validation of lead vaccine molecules.• Led the CGRP program for migraine pain disorder as the project leader• Designed and optimized in vitro & ex vivo serological assays• Evaluated serological antigen-specific antibody abundance, ligand competition capability of antibodies• Developed workflows for B cell phenotype characterization of vaccinated animals

(Fierce 15 Biotech of 2023 with Four Ph1 Programs) Led and advanced the company’s signature TNFR2 antibody program from ideation to IND filing, facilitating a successful Series D fundraising round.• Managed a 25-member matrix team for the TNFR2 (HFB200301) program• Developed HFB200301, a first-in-class TNFR2 antibody therapy, from ideation to IND filing in 3 years• Led IND submission that resulted in a $75M Series D round• Demonstrated superior 2x anti-tumor efficacy compared to PD1 antibody in preclinical models• Developed in vitro bioassays for CD8 and NK-targeted immuno-stimulations and analyzed cell profiles of primary T, B, NK, macrophage, myeloid cells • Conducted in vivo studies for efficacy, PD, PK in humanized, syngeneic or orthotopic models as well as NHP toxicity and translational analysis to guide biomarker and indication selection• Progress published at AACR sequentially at 2020 and 2021. Patent issued 2 year after project initiation [ HiFiBiO Therapeutics Closes $75 Million Series D to Accelerate Lead Immuno-Oncology Programs ] [ Ph1 Safety Study of HFB200301 in Adult Patients with Solid Tumors ] [ 2021 AACR: MoA and Biomarker strategy for HFB200301 ]

(Start-up Spun Out from Harvard Postdoc Research) Developed platform capabilities to evaluate compound derivatives and served as a point of contact between founders and the management team.• Supported the humanization and in vivo validation of PNT001, a cis-pT231-Tau antibody• Coordinated SAR library for lead selection of Pin1 inhibitors• Managed CRO relationships for biology, biophysics, and animal evaluations [ Ph1 Safety and Tolerability Study of PNT001 in Healthy Adults, NCT04096287 ]

(Susan G. Komen postdoctoral fellow in the laboratory of Kun Ping Lu)• Investigated oncogenic MoA of cancer cells signature to explore inhibitors for Pin1 isomerase• Designed and optimized a fluorescence polarization (FP)-based HTS platform for Pin1 inhibitors• Identify potent Pin1 inhibitors from the compound library of 400,000 compound chemicals• Applied biochemical assays to profile compound affinity and potency • Developed and executed in vitro cell-based assays to characterize compound pharmacodynamics • Elucidated in vivo PD and efficacy using xenograft and transgenic mouse models.• Established a lupus-prone, Pin1 KO mouse model to validate disease phenotypes lacking Pin1• Characterized and developed biologics against Alzheimer disease in cellular or animals models • Served as a mentor to junior postdoctoral and Ph.D researchers and high school interns.

PhD in the laboratory of Ching-Shih Chen• Developed a novel class of energy restriction-mimetic agent (ERMA), OSU-CG12• Identified anti-tumor MoA of OSU-03012 as an E3 ligase degrader for oncoprotein degradations• Demonstrated the pivotal importance of OSU-CG12 in reducing glycolytic rate and tumor growth • Identified pharmacodynamics profile of OSU-CG12 in mammalian cell lines• Developed multiple gain-of-function and loss-of-function systems to examine drug-induced ubiquitin protease system (UPS) degradation, cancer cell viability, cell cycle- and apoptosis mechanism